Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00245947 |
Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn’s disease.
Condition | Intervention | Phase |
---|---|---|
Crohn's Disease |
Drug: ERB-041 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn’s Disease |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Other inclusions apply
Exclusion Criteria:
Within 48 hours before randomization
Other exclusions applies
Study ID Numbers: | 3142A3-102 |
Study First Received: | October 26, 2005 |
Last Updated: | May 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00245947 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Crohn's Disease Inflammation |
Crohn's Disease Digestive System Diseases Gastrointestinal Diseases Ileitis Enteritis Crohn Disease |
Inflammatory Bowel Diseases Gastroenteritis Intestinal Diseases Ileal Diseases Inflammation |
Digestive System Diseases Gastrointestinal Diseases Ileitis Enteritis Crohn Disease |
Inflammatory Bowel Diseases Intestinal Diseases Gastroenteritis Ileal Diseases |